Trials / Active Not Recruiting
Active Not RecruitingNCT05319574
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
Preoperative Stereotactic Body Radiotherapy and Platinum-based Doublet Chemotherapy Plus Tislelizumab (Immunotherapy) for Operable Stage II to III EGFR Wild-type Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for operable stage II to III non-small cell lung cancer (NSCLC) prior to surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT | Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy |
| DRUG | Tislelizumab | 200mg q3w for two cycles administrated concurrently with chemotherapy |
Timeline
- Start date
- 2022-04-24
- Primary completion
- 2023-06-25
- Completion
- 2026-05-31
- First posted
- 2022-04-08
- Last updated
- 2025-06-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05319574. Inclusion in this directory is not an endorsement.